文章：

胃肠道间质瘤的免疫治疗现状

Current status of immunotherapy for gastrointestinal stromal tumor 

原文发布日期：2017-02-10 

英文摘要：

Gastrointestinal stromal tumors (GIST) contain tumor-infiltrating immune cells and their presence provides an opportunity and rationale for developing effective forms of immunotherapy. The types of tumor-infiltrating inflammatory cells and relevant immune checkpoint inhibitors are the focus of active investigation. The most numerous tumor-infiltrating inflammatory cells are tumor-associated macrophages (TAMs) and CD3+ T cells. Studies have shown that patients with GISTs that harbor increased numbers of CD3+ T cells have better outcomes. However, the clinical behavior of GIST has not been shown to correlate with the number of TAMs. The biological significance of other less frequent tumor-infiltrating immune cells including tumor-infiltrating neurtrophils (TINs), natural killer cells (NKs), B cells, dendritic cells (DCs) remains unclear. The immune checkpoint inhibitors CTLA-4, PD1/PDL1 and TIM3/galectin-9 are molecules that can be targeted by synthesized antibodies. Clinical and pre-clinical trials using this approach against immune checkpoint inhibitors, anti-KIT antibody and the generation of chimeric antigen receptor (CAR) T-cells have shown promising results. The treatment of GIST with immunotherapy is complex and evolving; this article reviews its current status for patients with GISTs. 

摘要翻译： 

胃肠道间质瘤（GIST）中含有肿瘤浸润免疫细胞，这一特性为开发有效的免疫疗法提供了理论基础和实践机遇。目前研究重点集中于肿瘤浸润炎症细胞的类型及相关免疫检查点抑制剂。其中数量最多的肿瘤浸润炎症细胞是肿瘤相关巨噬细胞（TAMs）和CD3+ T细胞。研究表明，CD3+ T细胞数量增加的GIST患者预后更佳，但TAMs的数量与GIST临床行为尚未发现明确关联。其他较少见的肿瘤浸润免疫细胞（包括肿瘤浸润中性粒细胞TINs、自然杀伤细胞NKs、B细胞、树突状细胞DCs）的生物学意义仍不明确。针对免疫检查点抑制剂CTLA-4、PD1/PDL1和TIM3/半乳糖凝集素-9的合成抗体靶向治疗已进入探索阶段，针对免疫检查点抑制剂的临床前及临床试验、抗KIT抗体疗法以及嵌合抗原受体（CAR）T细胞的生成均显示出令人鼓舞的结果。GIST的免疫治疗体系复杂且处于快速发展中，本文旨在综述该领域当前的研究进展。

原文链接：

Current status of immunotherapy for gastrointestinal stromal tumor